American Health & Drug Benefits

Recent Articles

Multiple Myeloma

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Phoebe Starr

Emerging Therapies

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Phoebe Starr

Leukemia, Value-Based Care

First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML

Chase Doyle

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH

Stakeholder Perspective

Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?

by Atheer A. Kaddis, PharmD

Conference Highlights ASH

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

Wayne Kuznar

Clinical, Original Research

Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan

Qingqing Xu, MS, Sarah S. Laxa, PharmD, Omar Serna, PharmD, BCACP, Sujit S. Sansgiry, MS, PhD

Stakeholder Perspective

Improving Medication Use for Chronic Diseases by Reducing Costs, Increasing Patient Adherence

by F. Randy Vogenberg, PhD, FASHP

Healthcare Disrupters

Bye Bye Burnout?

Corporate Culture of Health: Elusive and Expensive

David B. Nash, MD, MBA

Most Popular Articles

Select Drug Profiles

Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations

Loretta Fala

Editorial

Bye Bye Burnout?

Clinical, Original Research

Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation

William P. Glasheen, PhD, Tristan Cordier, MPH, Rajiv Gumpina, MS, Gilbert S. Haugh, MS, Jared Davis, MD, MBA, Andrew Renda, MD, MPH

Select Drug Profiles

Zulresso (Brexanolone) First Drug Approved by the FDA Specifically for Postpartum Depression in Adults

Loretta Fala

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH

Editorial

Corporate Culture of Health: Elusive and Expensive

David B. Nash, MD, MBA

Web Exclusives

FDA Approvals, Lung Cancer

Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer

FDA Approvals

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Approvals, Lung Cancer

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation